Drugs that contain Asenapine Maleate
1. Saphris patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(1 year, 11 months from now) | |
| US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5763476 | ALLERGAN | Sublingual or buccal pharmaceutical composition |
Jun, 2020
(3 years ago) | |
|
US5763476 (Pediatric) | ALLERGAN | Sublingual or buccal pharmaceutical composition |
Dec, 2020
(3 years ago) | |
|
US8022228 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(2 years from now) | |
|
US7741358 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 12, 2018 |
| M(M-158) | Mar 12, 2018 |
| New Dosing Schedule(D-166) | Jan 13, 2020 |
| New Indication(I-597) | Jan 13, 2020 |
| Pediatric Exclusivity(PED) | Sep 12, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2014 |
| New Indication(I-629) | Sep 03, 2013 |
| New Indication(I-628) | Sep 03, 2013 |
NCE-1 date: 12 September, 2017
Market Authorisation Date: 12 March, 2015
Treatment: Method of treating schizophrenia and bipolar disorder; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: as adjunctive treatment to lithium or...
Dosage: TABLET;SUBLINGUAL
How can I launch a generic of SAPHRIS before it's drug patent expiration?
More Information on Dosage
SAPHRIS family patents
